Literature DB >> 16716962

Prevalence, comorbidity and impact of irritable bowel syndrome in Norway.

Per Olav Vandvik1, Stian Lydersen, Per G Farup.   

Abstract

OBJECTIVE: To study the prevalence of irritable bowel syndrome (IBS) and its comorbidity in a Norwegian adult population.
MATERIAL AND METHODS: In 2001, 11,078 inhabitants (aged 30-75 years) in Oppland County were invited to take part in a public health survey. A total of 4622 subjects (42%) completed the questionnaires on symptoms of IBS (Rome II criteria), comorbidity, health-care visits and medications. The impact of comorbidity on global health, working disability and use of health-care resources in subjects with IBS was explored by stepwise logistic regression.
RESULTS: The population prevalence of IBS was 388/4622 (8.4% (95% CI: 7.6-9.4%)) with a female predominance and an age-dependent decrease. The proportion who had consulted for IBS ranged from 51% among 30-year-olds to 79% in 75-year-olds (p=0.05). IBS was associated with musculoskeletal complaints (OR = 2.4-3.4 for six different items), fibromyalgia (OR = 3.6 [2.7-4.8]), mood disorder (OR = 3.3 (2.6-4.3)), reduced global health (OR = 2.6 (2.1-3.2)), working disability (OR = 1.6 (1.2-2.1)), more frequent health-care visits and use of medications (OR 1.7-2.3). When controlling for comorbidity, reduced global health (OR = 1.5 (1.1-2.0)) and use of alternative health care (OR = 1.7 (1.3-2.4)) remained associated with IBS. Severity of abdominal pain/discomfort was a predictor of having to seek a physician for IBS (OR = 1.3 (1.2-1.5)).
CONCLUSIONS: Symptoms of IBS were reported by 8% of Norwegian adults and had resulted in consultations with physicians for the majority in the long run. Subjects with IBS in the community were characterized by frequent somatic and psychiatric comorbidity. Their observed reduced health, working disability and increased use of health resources were largely explained by comorbid symptoms and disorders.

Entities:  

Mesh:

Year:  2006        PMID: 16716962     DOI: 10.1080/00365520500442542

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  39 in total

1.  Altering the gastrointestinal flora in patients with functional bowel disorders: a way ahead?

Authors:  Magnus Simrén
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

2.  Investigation of the effect of military stress on the prevalence of functional bowel disorders.

Authors:  Xian-Zhao Yu; Hai-Feng Liu; Zhen-Xue Sun
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

3.  Endocrine cells in the ileum of patients with irritable bowel syndrome.

Authors:  Magdy El-Salhy; Odd Helge Gilja; Doris Gundersen; Jan Gunnar Hatlebakk; Trygve Hausken
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

4.  Irritable bowel syndrome: diagnosis and pathogenesis.

Authors:  Magdy El-Salhy
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

5.  How does comorbidity affect cost of health care in patients with irritable bowel syndrome? A cohort study in general practice.

Authors:  Per A Johansson; Per G Farup; Andrea Bracco; Per O Vandvik
Journal:  BMC Gastroenterol       Date:  2010-03-17       Impact factor: 3.067

6.  Prevalence of mood and anxiety disorder in self reported irritable bowel syndrome (IBS). An epidemiological population based study of women.

Authors:  Arnstein Mykletun; Felice Jacka; Lana Williams; Julie Pasco; Margaret Henry; Geoffrey C Nicholson; Mark A Kotowicz; Michael Berk
Journal:  BMC Gastroenterol       Date:  2010-08-05       Impact factor: 3.067

7.  The current prevalence of irritable bowel syndrome in Asia.

Authors:  Full-Young Chang; Ching-Liang Lu; Tseng-Shing Chen
Journal:  J Neurogastroenterol Motil       Date:  2010-10-30       Impact factor: 4.924

Review 8.  Is irritable bowel syndrome an organic disorder?

Authors:  Magdy El-Salhy; Doris Gundersen; Odd Helge Gilja; Jan Gunnar Hatlebakk; Trygve Hausken
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

9.  Development and validation of the irritable bowel syndrome scale under the system of quality of life instruments for chronic diseases QLICD-IBS: combinations of classical test theory and generalizability theory.

Authors:  Pingguang Lei; Guanghe Lei; Jianjun Tian; Zengfen Zhou; Miao Zhao; Chonghua Wan
Journal:  Int J Colorectal Dis       Date:  2014-08-01       Impact factor: 2.571

10.  Who Uses CAM? A Narrative Review of Demographic Characteristics and Health Factors Associated with CAM Use.

Authors:  Felicity L Bishop; G T Lewith
Journal:  Evid Based Complement Alternat Med       Date:  2008-03-13       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.